Bone associated with implants in diabetic and insulin-treated rats.
OBJECTIVE
Diabetes is an increasingly prevalent disease with oral health manifestations. While diabetes clearly has an affect on bone, its impact on the healing of bone associated with dental implants is not completely understood. The purpose of this study was to measure bone response to implants in uncontrolled and insulin-controlled diabetic rats.


METHODS
One hundred and fifty-two rats were divided into control, diabetic, and insulin groups. Rats received streptozotocin (65 mg/kg) to induce diabetes; animals in the insulin group also received a subcutaneous slow-release insulin implant. Titanium alloy implants (1.5 x 8 mm) were placed in the proximal tibiae of animals. Implants were harvested at 2, 7, 14, and 24 days and examined histologically. Bone or bone-like tissue adjacent to implants was quantified as a percent. Data were compared using a two-way analysis is variance (ANOVA) with time and treatment as primary independent factors.


RESULTS
Time and treatment were significant factors in predicting bone response to implants (P<0.0001). Mean bone volume peaked at day 7 and decreased over time to day 24. Mean bone volume percent at 2, 7, 14, and 24 days (+/-SD) was 8.2 (+/-8), 22.9 (+/-8), 18.8 (+/-10), and 14.9 (+/-9), respectively. Mean total bone volume percent (adjusted for day) for control, diabetic, and insulin groups (+/-SD) was 12.4 (+/-9), 22.6 (+/-10), and 17 (+/-7), respectively. Bone volume adjacent to implants in diabetic rats was significantly greater than controls (P<0.05). Diabetic animals treated with insulin were not statistically different from controls.


CONCLUSIONS
Induction of diabetes with STZ is associated with increased bone response compared with controls. This response was mediated by treatment with insulin.
McCracken
Michael S
MS
UAB School of Dentistry, SDB 606, 1919 Seventh Avenue South, Birmingham, AL 35294, USA. mikemc@uab.edu
Aponte-Wesson
Ruth
R
Chavali
Ramakiran
R
Lemons
Jack E
JE
D000818:Animals; D015519:Bone Density / Q000502:physiology; D001857:Bone Matrix / Q000473:pathology; D003722:Dental Alloys; D015921:Dental Implants; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000503:physiopathology*; D004195:Disease Models, Animal; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007091:Image Processing, Computer-Assisted; D015918:Infusion Pumps, Implantable; D007332:Insulin Infusion Systems; D016348:Osseointegration / Q000502:physiology*; D010011:Osteocytes / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D013977:Tibia / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D014025:Titanium; D014945:Wound Healing / Q000502:physiology
D003722:Dental Alloys; D015921:Dental Implants; D007004:Hypoglycemic Agents; D013311:Streptozocin; D014025:Titanium